Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).
For eligible patients ages 6+ prescribed a Takeda HAE therapy.
Takeda's OnePath program helps patients navigate insurance access and coverage issues. Patient Support Managers can help your patients understand their coverage for CINRYZE and provide information about financial assistance options.
OnePath Co-Pay Assistance Program*
OnePath understands that costs associated with treatment can act as a barrier to patient access. The OnePath Co-pay Assistance Program helps eligible insured patients cover certain out-of-pocket treatment costs. This program will also cover certain infusion expenses for eligible patients, up to the program maximum, regardless of financial status.*
Complete the form with your patient and fax it to 1-855-ONEPATH(1-855-663-7284).